Bills

SB 786: Prescription drug pricing.

  • Session Year: 2023-2024
  • House: Senate

Current Status:

Passed

(2023-10-07: Chaptered by Secretary of State. Chapter 414, Statutes of 2023.)

Introduced

First Committee Review

First Chamber

Second Committee Review

Second Chamber

Enacted

Version:

Existing federal law requires the United States Secretary of Health and Human Services to enter into an agreement with each manufacturer of covered outpatient drugs to ensure the amount a covered entity is required to pay for those drugs does not exceed the average manufacturer price of the drug under the federal Medicaid program. Existing state law requires a covered entity to dispense only drugs subject to these federal pricing requirements to Medi-Cal beneficiaries. Existing law defines a covered entity to include a federally qualified health center and entities receiving specified grants and federal funding.

This bill would prohibit a pharmacy benefit manager from discriminating against a covered entity or its pharmacy in connection with dispensing a drug subject to federal pricing requirements or preventing a covered entity from retaining the benefit of discounted pricing for those drugs.

Discussed in Hearing

Senate Floor43SEC
Sep 6, 2023

Senate Floor

Assembly Floor1MIN
Aug 24, 2023

Assembly Floor

Senate Floor3MIN
May 22, 2023

Senate Floor

Senate Standing Committee on Health22MIN
Apr 19, 2023

Senate Standing Committee on Health

View Older Hearings

News Coverage:

SB 786: Prescription drug pricing. | Digital Democracy